1. Home
  2. SLP vs CAPR Comparison

SLP vs CAPR Comparison

Compare SLP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLP
  • CAPR
  • Stock Information
  • Founded
  • SLP 1996
  • CAPR 2005
  • Country
  • SLP United States
  • CAPR United States
  • Employees
  • SLP N/A
  • CAPR N/A
  • Industry
  • SLP EDP Services
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SLP Technology
  • CAPR Health Care
  • Exchange
  • SLP Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • SLP 675.9M
  • CAPR 600.7M
  • IPO Year
  • SLP 1997
  • CAPR N/A
  • Fundamental
  • Price
  • SLP $18.32
  • CAPR $9.67
  • Analyst Decision
  • SLP Buy
  • CAPR Strong Buy
  • Analyst Count
  • SLP 7
  • CAPR 8
  • Target Price
  • SLP $40.40
  • CAPR $33.75
  • AVG Volume (30 Days)
  • SLP 571.2K
  • CAPR 3.3M
  • Earning Date
  • SLP 07-14-2025
  • CAPR 08-06-2025
  • Dividend Yield
  • SLP 0.32%
  • CAPR N/A
  • EPS Growth
  • SLP N/A
  • CAPR N/A
  • EPS
  • SLP 0.36
  • CAPR N/A
  • Revenue
  • SLP $78,564,000.00
  • CAPR $17,363,588.00
  • Revenue This Year
  • SLP $27.66
  • CAPR $258.96
  • Revenue Next Year
  • SLP $6.75
  • CAPR $8.02
  • P/E Ratio
  • SLP $51.73
  • CAPR N/A
  • Revenue Growth
  • SLP 21.49
  • CAPR N/A
  • 52 Week Low
  • SLP $16.72
  • CAPR $3.52
  • 52 Week High
  • SLP $49.05
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • SLP 29.54
  • CAPR 45.24
  • Support Level
  • SLP $16.78
  • CAPR $6.07
  • Resistance Level
  • SLP $17.70
  • CAPR $11.58
  • Average True Range (ATR)
  • SLP 1.15
  • CAPR 1.59
  • MACD
  • SLP -0.00
  • CAPR -0.23
  • Stochastic Oscillator
  • SLP 14.61
  • CAPR 44.57

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: